BACKGROUND: Approximately 50% of patients with advanced melanoma treated with first-line anti-PD-1 immunotherapy achieve clinical benefit. However, to date, there are no validated biomarkers for objective response (ORR), progression-free survival (PFS), or overall survival (OS) with this treatment. METHODS: We performed a unicentric retrospective analysis of ORR, PFS, and OS in 138 patients with advanced melanoma treated with first-line anti-PD-1 monoclonal antibodies. Baseline blood parameters were analyzed as potential predictive or prognostic biomarkers. ORR was assessed using both RECIST (Response Evaluation Criteria In Solid Tumors) v.1.1 and iRECIST (Immune Response Evaluation Criteria In Solid Tumors). Survival analysis was performed using Kaplan-Meier curves, and comparisons were made using the log-rank test. Multivariate Cox regression analysis was used to determine independent prognostic factors for survival, and a logistic regression model was used for response. RESULTS: The median follow-up was 44.1 (95% confidence interval [CI]: 40.4-49.4) months. Elevated pretreatment lactate dehydrogenase (LDH) level and systemic immune-inflammation index (SII) were negative prognostic factors for PFS. However, only LDH remained statistically significant on multivariate analysis [hazard ratio (HR) 1.72, 95% CI: 1.09-2.70, p = 0.019, HR 1.69, 95% CI: 0.95-3.00, p = 0.072]. Increased pretreatment LDH level and SII were both negative prognostic factors for OS on multivariate analysis (HR 2.25, 95% CI: 1.35-3.75, p = 0.002, HR 2.37, 95% CI: 1.29-4.37, p = 0.006). CONCLUSIONS: Elevated pretreatment levels of SII and LDH were shown to be independent negative prognostic factors for OS. According to the nomogram for OS, which considers a combination of pretreatment parameters including LDH and SII, it is possible to predict 24-month OS in the first line of anti-PD-1 therapy.

Department of Clinical Oncology Faculty of Medicine Charles University in Pilsen and Krajská Zdravotní Masaryk Hospital Ústí nad Labem Czech Republic

Department of Dermatology and Venereology 3rd Faculty of Medicine Charles University and Královské Vinohrady University Hospital Prague Czech Republic

Department of Dermatology and Venereology NOVA Medical School NOVA University Lisbon Lisbon Portugal

Department of Dermatology and Venereology St Joseph Local Health Unit Lisbon Portugal

Institute of Biostatics and Analysis Ltd Brno Czech Republic

Zobrazit více v PubMed

Pasini L., “Genome‐Wide Profiling of Copy Number Alterations in Cancer Focus on Melanoma,” Biomedical Reviews 24 (2013): 11–24.

Sladden M. J., Balch C., Barzilai D. A., et al., “Surgical Excision Margins for Primary Cutaneous Melanoma,” Cochrane Database of Systematic Reviews 7 (2009): 1–31. PubMed

Garbe C., Amaral T., Peris K., et al., “European Consensus‐Based Interdisciplinary Guideline for Melanoma. Part 1: Diagnostics: Update 2022,” European Journal of Cancer 170 (2022): 236–255, 10.1016/j.ejca.2022.03.008. PubMed DOI

Whiteman D. C., Green A. C., and Olsen C. M., “The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations Through 2031,” Journal of Investigative Dermatology 136 (2016): 1161–1171. PubMed

Keung E. Z., Balch C. M., Thompson J. F., et al., “Melanoma Prognosis and Staging,” in Cutaneous Melanoma, 6th ed., ed. Balch C. M., Atkins M. B., Garbe C., Gershenwald J. E., Halpern A. C., and Kirkwood J. M. (Springer Nature Switzerland AG, 2020), 271–297.

Wolchok J. D., Chiarion‐Sileni V., Rutkowski P., et al., “Final, 10‐Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 392, no. 1 (2025): 11–22, 10.1056/NEJMoa2407417. PubMed DOI PMC

Long G. V., Carlino M. S., McNeil C., et al., “Pembrolizumab Versus Ipilimumab for Advanced Melanoma: 10‐Year Follow‐Up of the Phase III KEYNOTE‐006 Study,” Annals of Oncology 35 (2024): 1191–1199. PubMed

Long G. V., Stephen Hodi F., Lipson E. J., et al., “Overall Survival and Response With Nivolumab and Relatlimab in Advanced Melanoma,” NEJM Evidence 2 (2023): 1–10. PubMed

Seth R., Agarwala S. S., Messersmith H., et al., “Systemic Therapy for Melanoma: ASCO Guideline Update,” Journal of Clinical Oncology 41 (2023): 4794–4820. PubMed

Amaral T., Ottaviano M., Arance A., et al., “Cutaneous Melanoma: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow‐Up,” Annals of Oncology S0923‐7534 (2024): 04912–3. PubMed

“NCCN Clinical Practice Guidelines in Oncology, Cutaneous Melanoma. Version 3.2024,” accessed September 23, 2024, https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf.

Robert C., Ribas A., Schachter J., et al., “Pembrolizumab Versus Ipilimumab in Advanced Melanoma (KEYNOTE‐006): Post‐Hoc 5‐Year Results From an Open‐Label, Multicentre, Randomised, Controlled, Phase 3 Study,” Lancet Oncology 20 (2019): 1239–1251. PubMed

Seedor R. S. and Orloff M., “Treatment of Metastatic Melanoma in the Elderly,” Current Oncology Reports 24 (2022): 825–833. PubMed

De Luca R., Meraviglia S., Blasi L., Maiorana A., and Cicero G., “Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients,” Current Oncology 27 (2020): 75–80. PubMed PMC

Lim S. Y., da Silva I. P., Adegoke N. A., et al., “Size Matters: Integrating Tumour Volume and Immune Activation Signatures Predicts Immunotherapy Response,” Molecular Cancer 23 (2024): 228–333. PubMed PMC

Busam K. J., “Desmoplastic Melanoma,” Clinical Dermatology S0738‐081X (2024): 00174–3.

Poh A., “Single‐Agent PD‐1 Blockade Is “Treatment of Choice” for Desmoplastic Melanoma,” Cancer Discovery 13 (2023): 7. PubMed

D'Angelo S. P., Larkin J., Sosman J. A., et al., “Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis,” Journal of Clinical Oncology 35 (2017): 226–235, 10.1200/JCO.2016.67.9258. PubMed DOI PMC

Nakamura Y., Namikawa K., Kiniwa Y., et al., “Efficacy Comparison Between Anti‐PD‐1 Antibody Monotherapy and Anti‐PD‐1 Plus Anti‐CTLA‐4 Combination Therapy as First‐Line Immunotherapy for Advanced Acral Melanoma: A Retrospective, Multicenter Study of 254 Japanese Patients,” European Journal of Cancer 176 (2022): 78–87. PubMed

Tawbi H. A., Forsyth P. A., Hodi F. S., et al., “Long‐Term Outcomes of Patients With Active Melanoma Brain Metastases Treated With Combination Nivolumab Plus Ipilimumab (CheckMate 204): Final Results of an Open‐Label, Multicentre, Phase 2 Study,” Lancet Oncology 22 (2021): 1692–1704. PubMed PMC

Albrecht L. J., Livingstone E., Zimmer L., and Schadendorf D., “The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma,” Current Oncology Reports 25 (2023): 647–657. PubMed PMC

Kluger H., Barrett J. C., Gainor J. F., et al., “Society for Immunotherapy of Cancer (SITC) Consensus Definitions for Resistance to Combinations of Immune Checkpoint Inhibitors,” Journal for Immunotherapy of Cancer 11 (2023): e005921. PubMed PMC

Shui I. M., Scherrer E., Frederickson A., et al., “Resistance to Anti‐PD1 Therapies in Patients With Advanced Melanoma: Systematic Literature Review and Application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce Anti‐PD1 Resistance Definitions,” Melanoma Research 32 (2022): 393–404. PubMed

Hassel J. C., Zimmer L., Sickmann T., et al., “Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti‐PD‐1‐Directed Immune Checkpoint Inhibition,” Cancers (Basel) 15, no. 13 (2023): 3448–3470, 10.3390/cancers15133448. PubMed DOI PMC

Ravindranathan D., Master V. A., and Bilen M. A., “Inflammatory Markers in Cancer Immunotherapy,” Biology (Basel) 10 (2021): 325–336. PubMed PMC

Poletto S., Paruzzo L., Nepote A., Caravelli D., Sangiolo D., and Carnevale‐Schianca F., “Predictive Factors in Metastatic Melanoma Treated With Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective,” Cancers (Basel) 16 (2023): 101. PubMed PMC

Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., and Ford R., “New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1),” European Journal of Cancer 45 (2009): 228–247. PubMed

Seymour L., Bogaerts J., Perrone A., et al., “iRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics,” Lancet Oncology 18 (2017): 143–152. PubMed PMC

National Cancer Institute, National Institutes of Health, US Department of Health and Human Services , “Common Terminology Criteria for Adverse Events (CTCAE), ver. 5.0,” 2017, [WWW document], accessed October 20, 2024, https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Qiick_Reference_8.5x11.pdf.

Zhang W., Tan Y., Li Y., and Liu J., “Neutrophil to Lymphocyte Ratio as a Predictor for Immune‐Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta‐Analysis,” Frontiers in Immunology 14 (2023): 1–16. PubMed PMC

Kreuz M., de Moraes F. C. A., Sano V. K. T., Filho F. L. W., Silva A. L. S., and Kelly F. A., “Association of Baseline Neutrophil‐To‐Lymphocyte Ratio and Prognosis in Melanoma Patients Treated With PD‐1/PD‐L1 Blockade: A Systematic Review and Meta‐Analysis,” Melanoma Research 35 (2025): 1–10, 10.1097/CMR.0000000000001006. PubMed DOI

Gambichler T., Mansour R., Scheel C. H., Said S., Rached N. A., and Susok L., “Prognostic Performance of the Derived Neutrophil‐To‐Lymphocyte Ratio in Stage IV Melanoma Patients Treated With Immune Checkpoint Inhibitors,” Dermatologica 2, no. 2 (2022): 14–20, 10.3390/dermato2020003. DOI

Hernando‐Calvo A., García‐Alvarez A., Villacampa G., et al., “Dynamics of Clinical Biomarkers as Predictors of Immunotherapy Benefit in Metastatic Melanoma Patients,” Clinical & Translational Oncology 23 (2021): 311–317. PubMed

Yan O., Shufang L., Qiangqiang G., et al., “Prognostic Value of Inflammatory Markers NLR, PLR, LMR, dNLR, ANC in Melanoma Patients Treated With Immune Checkpoint Inhibitors: a Meta‐Analysis and Systematic Review,” Frontiers in Immunology 15 (2024): 1482746. PubMed PMC

Wan L., Wu C., Luo S., and Xie X., “Prognostic Value of Lymphocyte‐To‐Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors,” Disease Markers 2022 (2022): 3610038. PubMed PMC

Mesti T., Grašič Kuhar C., and Ocvirk J., “Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment With Immune Checkpoint Inhibitors,” Biomedicine 11 (2023): 749–761. PubMed PMC

Ekinci F., Balcik O. Y., Demir B., Gursoy P., Ozveren A., and Erdogan A. P., “Systemic Immune Inflammation Index as a Key Marker of Survival and Immune‐Related Adverse Events in Immune Checkpoint Inhibitor Therapy,” Journal of the College of Physicians and Surgeons–Pakistan 32 (2022): 996–1003. PubMed

Xu Y., Ma K., Zhang F., et al., “Association Between Baseline Creactive Protein Level and Survival Outcomes for Cancer Patients Treated With Immunotherapy: A Meta Analysis,” Experimental and Therapeutic Medicine 26 (2023): 361. PubMed PMC

Zhang Z., Zhang F., Yuan F., et al., “Pretreatment Hemoglobin Level as a Predictor to Evaluate the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Non‐Small Cell Lung Cancer,” Therapeutic Advances in Medical Oncology 12 (2020): 1–10. PubMed PMC

da Pires Silva I., Ahmed T., McQuade J. L., et al., “Clinical Models to Define Response and Survival With Anti‐PD‐1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma,” Journal of Clinical Oncology 40, no. 10 (2022): 1068–1080, 10.1200/JCO.21.01701. PubMed DOI

Xu J., Zhao J., Wang J., Sun C., and Zhu X., “Prognostic Value of Lactate Dehydrogenase for Melanoma Patients Receiving Anti‐PD‐1/PD‐L1 Therapy: A Meta‐Analysis,” Medicine (Baltimore) 100 (2021): e25318. PubMed PMC

Janka E. A., Várvölgyi T., Sipos Z., et al., “Predictive Performance of Serum S100B PubMed PMC

Liang X., Zhou S., and Xiao Z., “Prognostic Value of Lactate Dehydrogenase in Patients With Uveal Melanoma Treated With Immune Checkpoint Inhibition,” Aging (Albany NY) 15 (2023): 8770–8781. PubMed PMC

Li D., Sun Y., Le J., et al., “Predictors of Survival in Immunotherapy‐Based Treatments in Advanced Melanoma: a Meta‐Analysis,” International Journal of Dermatology 64 (2025): 15–23. PubMed

Baenke F., Dhormen N., Gottlieb E., and Marais R., “6 Melanoma Metabolism,” in Melanoma, 1st ed., ed. Fischer D. E. and Bastian B. C. (Springer New York, 2019), 99–122.

Egberts F., Kotthoff E. M., Gerdes S., Egberts J. H., Weichenthal M., and Hauschild A., “Comparative Study of YKL‐40, S‐100B and LDH as Monitoring Tools for Stage IV Melanoma,” European Journal of Cancer 48 (2012): 695–702. PubMed

Edge S. B., Byrd D. R., Compton C. C., Fritz A. G., Greene F. L., and Trotti A., “Part VI Skin, 31. Melanoma of the Skin,” in AJCC Cancer Staging Manual, 7th ed., ed. Edge S. B., Byrd D. R., Compton C. C., Fritz A. G., Greene F. L., and Trotti A. (Springer‐Verlag, 2010), 325–346.

Guven D. C., Aktepe O. H., Yildirim H. C., Celik I., and Kilickap S., “Higher Systemic Immune‐Inflammation Index (SII) Levels Are Associated With Poorer Survival in Immunotherapy‐Treated Melanoma Patients,” European Journal of Medical Informatics 5 (2021): 409–413.

Lee J. H., Hyung S., Lee J., and Choi S. H., “Visceral Adiposity and Systemic Inflammation in the Obesity Paradox in Patients With Unresectable or Metastatic Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: a Retrospective Cohort Study,” Journal for Immunotherapy of Cancer 10 (2022): e005226. PubMed PMC

Fest J., Ruiter R., Mulder M., et al., “The Systemic Immune‐Inflammation Index Is Associated With an Increased Risk of Incident Cancer‐A Population‐Based Cohort Study,” International Journal of Cancer 146 (2020): 692–698. PubMed PMC

Grivennikov S. I., Greten F. R., and Karin M., “Immunity, Inflammation, and Cancer,” Cell 140 (2010): 883–899. PubMed PMC

Balkwill F. and Mantovani A., “Inflammation and Cancer: Back to Virchow?,” Lancet 357 (2001): 539–545. PubMed

Hu B., Yang X. R., Xu Y., et al., “Systemic Immune‐Inflammation Index Predicts Prognosis of Patients After Curative Resection for Hepatocellular Carcinoma,” Clinical Cancer Research 20 (2014): 6212–6222. PubMed

Bhave P., Ahmed T., Lo S. N., et al., “Efficacy of Anti‐PD‐1 and Ipilimumab Alone or in Combination in Acral Melanoma,” Journal for Immunotherapy of Cancer 10 (2022): e004668. PubMed PMC

Dugan M. M., Perez M. C., Karapetyan L., and Zager J. S., “Management of Acral Lentiginous Melanoma: Current Updates and Future Directions,” Frontiers in Oncology 14 (2024): 1323933. PubMed PMC

Hassel J. C., Piperno‐Neumann S., Rutkowski P., et al., “Three‐Year Overall Survival With Tebentafusp in Metastatic Uveal Melanoma,” New England Journal of Medicine 389 (2023): 2256–2266. PubMed PMC